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Abstract
Objectives: Recent large cohort studies suggest an association between high plasma 
prolactin and cardiovascular mortality. The objective of this systematic review was 
to systematically assess the effect of reducing prolactin with dopamine agonist on 
established cardiovascular risk factors in patients with prolactinomas.
Design: Bibliographical search was done until February 2019 searching the following 
databases: PubMed, EMBASE, WHO and LILAC. Eligible studies had to include participants 
with verified prolactinomas where metabolic variables were assessed before and after at 
least 2 weeks treatment with dopamine agonists.
Methods: Baseline data and outcomes were independently collected by two investigators. 
The study was registered with PROSPERO (registration number CRD42016046525).
Results: Fourteen observational studies enrolling 387 participants were included. The 
pooled standardized mean difference of the primary outcome revealed a reduction 
of BMI and weight of −0.21 (95% CI −0.37 to −0.05; P = 0.01; I2 = 71%), after treatment. 
Subgroup analysis suggested that the reduction of weight was primarily driven by 
studies with high prolactin levels at baseline (P = 0.04). Secondary outcomes suggested 
a small decrease in waist circumference, a small-to-moderate decrease in triglycerides, 
fasting glucose levels, HOMA-IR, HbA1c and hsCRP, and a moderate decrease in LDL, 
total cholesterol and insulin.
Conclusion: This systematic review suggests a reduction of weight as well as an improved 
lipid profile and glucose tolerance after treatment with dopamine agonist in patients with 
prolactinomas. These data are based on low-quality evidence.
Introduction
In recent large cohort studies, high prolactin levels within 
and above the normal physiological range have been 
associated with increased risk of cardiovascular mortality 
(1, 2, 3). It is speculated whether this association is mediated 
through prolactin-induced increase in cardiovascular 
risk factors including obesity, dyslipidemia and insulin 
resistance (4, 5, 6, 7, 8, 9, 10). In a German population-
based cohort study, prolactin levels within the normal 
range showed a positive correlation to all-cause as well as 
cardiovascular mortality (1). Furthermore, prolactin levels 
prospectively correlated with higher levels of low-density 
lipoprotein (LDL) in women, and with hypertension and 
incidence of diabetes in men (11). In two large cohort 
studies hyperprolactinemia was associated with increased 
incidence of cardiovascular disease and cardiovascular 
mortality in men only (2, 3). However, the association 
between prolactin and excess disease burden is not 
consistent: In a case–control study with 1204 cases of 
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hyperprolactinemia, no increased morbidity or mortality 
was found (12), and in a large cohort, levels of prolactin 
did not differ between those participants who suffered 
from fatal or nonfatal coronary artery disease and those 
who did not (13).
Prolactin receptors are widely distributed in the liver 
(14), endocrine pancreas (15) and in adipose tissue (16) 
pointing to a possible direct metabolic effect of prolactin. 
A number of small studies have found that prolactin 
levels are associated with inflammation, endothelial 
dysfunction, insulin resistance and dyslipidemia that could 
contribute to cardiovascular complications (7, 17, 18, 19, 
20). Furthermore, prolactin levels correlated with insulin 
resistance in patients with polycystic ovary syndrome (21).
Dopamine is the natural negative regulator of 
prolactin release from the anterior pituitary gland, 
and dopamine D2 receptor agonists are the first line of 
treatment for most patients with prolactinoma.
A link between high prolactin levels and 
cardiovascular mortality would have important clinical 
implications. According to current guidelines (22), 
asymptomatic patients with hyperprolactinemia are 
not necessarily offered treatment; the same is true for 
secondary hyperprolactinemia as a side effect to widely 
used medications, such as antipsychotic drugs or in 
patients with kidney failure.
The purpose of this systematic review was to 
systematically assess the metabolic effects of dopamine 
agonist treatment in patients with prolactinomas.
Methods
Study design
A systematic review and meta-analysis. The study 
was registered with PROSPERO (registration number 
CRD42016046525).
Study selection
Eligible studies were observational or randomized clinical 
trials assessing the effect of dopamine agonist treatment 
in patients with prolactinomas verified by MRI or CT scan. 
For inclusion, the studies should report on metabolic 
variables before and after dopamine-agonist treatment. 
Patients should have been treated with dopamine agonist 
for more than 2 weeks. Studies that included patients with 
other treatments for prolactinomas, for example, surgical 
resection or radiotherapy of the pituitary adenoma were 
not included. There was no age or language restriction.
Search strategy
The following bibliographical databases were searched 
until February 2019: PubMed, EMBASE, WHO and 
LILAC using the text words terms: (prolactin OR 
hyperprolactinemia OR prolactinoma) AND (dopamine 
agonist OR dostinex OR cabergoline OR bromocriptine). 
The search was restricted to titles.
One investigator (SB) conducted the main search. 
Based on title and abstract, obviously irrelevant titles were 
removed and the remaining studies were considered for 
inclusion after thorough review of the full manuscript.
Data extraction
Demographical data, baseline data of participants, study 
outcomes, diagnostic procedures, patient co-morbidity, 
hormone replacement among participants, type and 
duration of treatment, and results were independently 
collected by two investigators (SB, JF). In studies where 
more than one follow-up was reported, data from the latest 
follow-up, where the number and gender distributions of 
participants were reported, were included in the analysis.
Authors were contacted by mail in case of queries 
regarding reported data. Two requests were sent with 
14-days interval if no response was received after the first 
request.
Outcomes
Primary outcome
The primary outcome was change in weight or body mass 
index (BMI) from baseline to the end of the observation.
Secondary outcomes
Secondary outcomes were waist circumference (WC), 
total cholesterol, low-density lipoprotein (LDL), 
triglycerides (TRG), fasting plasma glucose, HOMA-IR, 
fasting serum insulin, glycated hemoglobin (HbA1c), 
plasma testosterone, luteinizing hormone (LH), follicle-
stimulating hormone (FSH), high-sensitivity C-reactive 
protein (hsCRP) and systolic and diastolic blood pressure.
Assessment of study quality
The risk of bias in the included studies was assessed by 
using the Newcastle–Ottawa Scale (NOS) for cohort 
studies as suggested by the Cochrane collaboration (23), 
which assesses selection bias, comparability and outcome 
modified for the current systematic review. Selection of 
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cases was awarded points if patients were consecutively 
approached for inclusion, if both genders were included 
in the study and if hypothyroidism was ruled out. In the 
outcome domain we assessed if the staff assessed weight 
or if weight was reported by the participants themselves, if 
staff were blinded to baseline weight and if attrition were 
less than 5% at follow-up. For each study, we assessed the 
above items providing each with assessment of ‘yes’ or 
‘no’. In case there was inadequate information to judge 
either ‘yes’ or ‘no’ we used ‘unclear’. The total risk of 
bias score was based on one point for each ‘yes’ in the 
selection bias domain or the outcome domain. We also 
included whether the study was conducted prospectively 
or retrospectively. We considered this item as posing a risk 
of random error opposed to a systematic error, which was 
assessed in the selection bias domain and the outcome 
domains and did not include this item in the total score 
which represents an estimated pooled risk of bias. Studies 
with a total score of 4 or more were considered with less 
risk of bias.
Statistical methods
For all outcomes we reported the pooled effect estimates 
using the standardized mean difference (SMD). SMD is the 
mean difference in outcome between the post- and pre-
intervention assessment divided by the pooled standard 
deviation (SD). The result is a unit free effect size and by 
convention, SMD of 0.2, 0.5 and 0.8 are considered small, 
medium and large effects sizes.
In case mean (x ̄) was not reported, we calculated the 
mean from median (m) and range (a–b) using the formula 
x̄ ≈ (a + 2m + b) / 4, as proposed by Hozo et  al. (24), and 
SD = (b - a) / 4. In case results were reported separately for 
men and women, a pooled mean and SD was calculated 
as recommended in Cochrane Handbook for Systematic 
Reviews (23).
We expected some degree of heterogeneity due to 
differences in population, duration of treatment and 
dose of DA, and we a priori planned to use random-effects 
analysis to pool estimates from included studies.
P values below 0.05 were considered significant.
For data analyses, we used Comprehensive Meta-
Analysis 2.0. The heterogeneity for each outcome was 
reported as I2.
Subgroup analysis
For the primary outcomes, weight and BMI, we planned 
to explore the potential effect of confounding variables: 
duration of treatment (<6 months was short duration 
of treatment vs duration of treatment of ≥6 months), 
percentage of included men, prolactin levels at baseline, 
percentage of macroprolactinoma, the effect of study design 
as well as the effect of risk of bias. The division of groups for 
subgroup analysis was based on the median value.
Deviation from the protocol
There have been some changes from the original protocol: 
the duration of treatment was found to be equivalent to 
follow-up in the included studies; therefore, no subgroup 
analysis on follow-up was performed. Comorbidities 
were an exclusion criterion in seven studies and were not 
reported in five studies, and as a result of the inconsistency 
in this data point, a subgroup analysis on comorbidities 
was not performed. Only three studies reported change 
of testosterone levels (6, 25, 26) or estradiol levels (25, 27, 
28) , which is why this subgroup analysis was abandoned. 
Mixed treatment modalities were added as exclusion 
criteria to the original protocol. In the data analysis we 
conducted subgroup analysis by study design and risk of 
bias in addition to the original protocol. To improve the 
clinical applicability of the analysis, the effect sizes are 
also presented as mean difference.
Results
Study selection and characteristics
The bibliographical search was conducted until February 
2019. As illustrated in Fig. 1, we included 14 observational 
studies assessing the effect of dopamine agonist therapy 
on metabolic variables in 387 patients with prolactinomas 
(4, 5, 6, 7, 8, 25, 26, 27, 28, 29, 30, 31, 32, 33).
As shown in Table 1, nine of the included studies were 
prospective (5, 7, 8, 26, 27, 28, 29, 30, 32), three studies 
(4, 25, 33) were retrospective and in two studies the design 
was not clearly stated (6, 31). As shown in Table 2, study 
participants were treated with cabergoline (CAB) in eight 
studies (4, 5, 7, 25, 26, 27, 30, 33), bromocriptine (BRC) 
in two studies (28, 31) and in four studies participants 
received either CAB or BRC (6, 8, 29, 32).
The median percentage of male participants was 
23% (range, 0–100%). The median of mean age was 37 
years (range, 27–42 years). The median percentages of 
study participants with macroprolactinoma were 31.5% 
(range, 13–78%). The range of mean plasma prolactin was 
2514–43,693 mU/L and the median follow-up time was 
6 months (range, 3–60 months). The median number 
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of participants that reached normoprolactinemia at 
follow-up was 97% (range, 56–100%) (4, 5, 6, 7, 8, 26, 27, 
28, 29, 30, 32).
Because of heterogeneity in reported data, it has not 
been possible to compare the data regarding treatment 
dosage: In two studies the dosage was not reported (8, 
29); two studies reported the initial dosage (27, 30), two 
studies reported a range of doses administered, without 
reporting a median dose (28, 31); one study reported 
the accumulated dose of 108 mg CAB administered over 
a mean period of 56.9 ± 46 months (33) and four studies 
reported doses administered in different periods of the 
studies (4, 5, 7, 26).
Raw data are presented in Supplementary Tables 3, 4, 
5, 6, and 7 (see section on supplementary data given at 
the end of this article.
In the nine studies reporting obesity at baseline, the 
median percentage of participants with overweight at 
baseline was 47% (range, 19–97%) (5, 6, 7, 8, 26, 27, 29, 
30, 31). The median fasting glucose levels at baseline 
were 5.2 mmol/L (range, 4.4–6.5), and median HbA1c was 
35.5 mmol/mol (34.4–36.8). The median mean value of 
LDL at baseline was 3.3 mmol/L (range, 2.8–3.7). Only 3 
of 14 studies reported on baseline levels of sex hormones. 
The prevalence of comorbidities was not reported, or 
participants with comorbidities were excluded, in 12 studies.
Assessment of risk of bias in included studies
None of the included studies had a control group and the 
comparability item was left out. No participants were lost 
to follow-up in 9 of 14 studies (4, 5, 25, 26, 28, 30, 31, 
32, 33), in four studies 7–40% of participants were not 
included in final analysis (6, 8, 27, 29), and in one study 
this item was unclear (7). Based on our modified NOS bias 
assessment, we found that eight studies had a high risk 
of bias, and five studies had a lesser risk of bias in the 13 
studies that reported on the primary outcome. Risk of bias 
for the primary outcome is presented in Table 1.
Primary outcome: the effect of dopamine agonist 
therapy on weight or body mass index
At follow-up, 12 studies reported change in BMI, one 
study reported change in weight exclusively and, finally, 
one study reported neither change in weight nor BMI. 
Therefore, 13 studies with 360 participants were available 
for analysis. The standardized mean change in BMI and 
Figure 1
Prisma flow chart.
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weight was −0.21 SMD (95% CI −0.37 to −0.05; P = 0.01) at 
follow-up compared to baseline values. For the 12 studies 
that only reported on BMI, the mean reduction in BMI 
after treatment was −1.17 BMI points (95% CI −1.99 to 
−0.38). The forest plot is presented in Fig. 2 and inspection 
of funnel plot (not shown) for primary outcome did not 
suggest publication bias.
Heterogeneity and subgroup analysis of 
primary outcome
The primary outcome was associated with an I2 of 71% 
suggesting substantial heterogeneity. Subgroup analysis 
suggested that the reduction of weight was −0.09 SMD 
(95% CI −0.16 to 0.06; P = 0.35; I2 = 0%) in studies with low 
prolactin levels at baseline compared to −0.33 SMD (95% 
CI −0.58 to −0.09; P = 0.008; I2 = 72%) in studies with high 
prolactin levels at baseline. As shown in Supplementary 
Table 1, no other subgroup analyses explained the 
observed heterogeneity.
Secondary outcomes
After treatment with DA, the pooled SMD suggested a small 
decrease in WC, a small-to-moderate decrease in TRG, 
fasting glucose levels, HOMA-IR, HbA1c and hsCRP, and 
a moderate decrease in LDL, total cholesterol and insulin 
(Supplementary Table 2). There was no change in blood 
pressure, a small increase in LF and FSH, no increase in 
estrogen and estradiol and a large increase in testosterone 
after treatment.
Adverse events from treatment
Adverse events were reported in 4 of 14 studies. In one 
study, 24% of the patients had a transient gastrointestinal 
intolerance to DA treatment (29). In another study 
non-specified transient side effects occurred in 21% (8). 
One study reported that no participants experienced 
adverse events (7) and in one study 87.5% of participants 
experienced nausea, dizziness and sleep disturbances 
during treatment (28). None of the studies reported 
serious adverse events.
Discussion
In this systematic review, we included 14 observational 
studies assessing the effect of DA treatment on metabolic 
variables in 387 patients with prolactinoma. For the 
primary outcome, weight and BMI, DA treatment 
significantly reduced body weight, with a weight 
reduction of 0.2 SMD. In addition, DA treatment was 
associated with small-to-moderate effects on all secondary 
endpoints except blood pressure, estrogen and estradiol. 
Too few studies reported on harmful events to provide any 
firm conclusions regarding this aspect of DA treatment in 
patients with prolactinomas.
A reduction in body weight was observed in 11 of 13 
included studies; however, the effect was most prevalent 
in studies with high prolactin levels at baseline. In 
concurrence with previous reports (17, 34, 35) the included 
studies had a high prevalence of obese participants at 
baseline which suggest an association between prolactin 
and obesity. There are several hypotheses, which may 
explain the observed reduction of weight after DA 
treatment in patients with hyperprolactinemia. One 
possible mechanism could be a direct effect of DA on 
metabolism. Randomized clinical trials of patients with 
type 2 diabetes and obesity suggest that quick-release BRC 
lowers HbA1c and fasting plasma glucose; however, in 
these studies a neutral effect on weight and lipid profile 
were observed (36, 37, 38).
Figure 2
Change in weight/BMI after dopamine receptor 
agonist treatment in patients with prolactinomas.
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Hyperprolactinemia causes hypogonadotropic 
hypogonadism and the observed effect on weight may be a 
result of restoration of eugonadism. It is well established that 
obesity can cause male hypogonadotropic hypogonadism. 
By contrast, it is debated whether hypogonadism induces 
obesity. Some studies have shown that low testosterone 
levels reduce the fat-to-muscle ratio, but do not alter body 
weight (39, 40, 41, 42). In opposition to these results a RCT 
(43) and two observational studies examining changes in 
body weight in male patients with hypogonadism before 
and after initiation of testosterone treatment found a mean 
decrease in BMI of approximately four BMI points (44, 45, 
46). For women obesity has been associated with higher 
levels of estrogens (41, 47) but to our knowledge no studies 
looking at weight change related to treatment of secondary 
hypogonadism in women has been published.
A direct effect of prolactin on adipocytes and lipid 
metabolism cannot be excluded, since prolactin receptors 
have been identified on adipose tissue (48). However, one 
in vitro study on human adipocytes from women in the 
fertile age found that prolactin inhibited lipid storage 
outside breast tissue (16), thereby not supporting a link 
between obesity and prolactin. It should be emphasized 
that the design of the included studies in the present meta-
analysis does not allow any conclusions on possible causal 
mechanisms between weight reduction and DA treatment.
For the secondary outcomes, we found improvement 
in all cardiovascular risk factors except blood pressure, 
estrogen and estradiol. We found a small decrease in WC, a 
small-to-moderate decrease in TRG, fasting glucose levels, 
HOMA-IR, HbA1c and hsCRP, and a moderate decrease in 
LDL, total cholesterol and fasting insulin levels.
DA treatment has a neutral effect on lipid profile (37). 
However, the favorable effect of quick-release BRC on 
glucose metabolism has led to the approval of BRC for 
treatment of type 2 diabetes by the FDA (49), and studies 
have found that BRC as add-on therapy in patients with 
type 2 diabetes lowers HbA1c (weighted mean difference, 
−6.52 mmol/mol; (95% CI −8.07 to −4.97) (37, 50, 51) 
which likely explains the observed effect on the glucose 
tolerance.
Reversal of hypogonadism might be contributing 
to the improvement in both lipid profile and glucose 
tolerance, but study results are conflicting: in a randomized 
double-blind trial allocating men with hypogonadism 
(n = 220) and type 2 diabetes or metabolic syndrome to 
testosterone supplementation or placebo; no consistent 
improvement was found in lipid profile or WC, but 
there was significant reduction in HOMA-IR (43). In two 
registry-based studies (n = 255 and n = 561) investigating 
males with hypogonadism, a significant reduction in total 
cholesterol, LDL, TRG, HbA1c, fasting blood glucose and 
CRP after testosterone treatment (44, 52).
There are several important limitations to the current 
review. No randomized trials were included, and all the 
reported outcomes were associated with moderate-to-
large heterogeneity. The strength of this review is that 
more than half of the included studies were prospective 
and the thorough and systematic approach regarding 
search strategy as well as data extraction and data 
synthesis. Furthermore, the protocol was made available 
in a publicly accessible database (Prospero) prior to data 
collection and analysis.
Today, large patient populations such as patients with 
renal failure and those receiving antipsychotic medication 
are not offered treatment for hyperprolactinemia. In 
case the findings from this systematic review could be 
replicated in studies of a higher evidence level, the clinical 
implications are potentially large.
Conclusion
This systematic review suggests a reduction of weight as 
well as an improved lipid profile and glucose tolerance 
after treatment with dopamine agonist in patients with 
prolactinomas. These data are based on low quality 
evidence.
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